JPS58201994A - 抗原特異的ヒト免疫グロブリンの生産方法 - Google Patents

抗原特異的ヒト免疫グロブリンの生産方法

Info

Publication number
JPS58201994A
JPS58201994A JP57084843A JP8484382A JPS58201994A JP S58201994 A JPS58201994 A JP S58201994A JP 57084843 A JP57084843 A JP 57084843A JP 8484382 A JP8484382 A JP 8484382A JP S58201994 A JPS58201994 A JP S58201994A
Authority
JP
Japan
Prior art keywords
human
cell
cells
immunoglobulin
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57084843A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0159878B2 (show.php
Inventor
Hideaki Hagiwara
秀昭 萩原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP57084843A priority Critical patent/JPS58201994A/ja
Priority to CA000428517A priority patent/CA1247538A/en
Priority to CS833566A priority patent/CZ280677B6/cs
Priority to SK3566-83A priority patent/SK279249B6/sk
Priority to DE3382764T priority patent/DE3382764T2/de
Priority to AT83902157T priority patent/ATE114189T1/de
Priority to EP83902157A priority patent/EP0109441B1/en
Priority to JP58502264A priority patent/JPS60501359A/ja
Priority to ES522585A priority patent/ES522585A0/es
Priority to HU832697A priority patent/HU190908B/hu
Priority to PH28943A priority patent/PH23031A/en
Priority to AU17729/83A priority patent/AU560595B2/en
Priority to PCT/US1983/000781 priority patent/WO1983004313A1/en
Priority to IT21217/83A priority patent/IT1203702B/it
Priority to KR1019830002232A priority patent/KR880001567B1/ko
Priority to IL68752A priority patent/IL68752A/xx
Priority to IT8348350A priority patent/IT8348350A0/it
Priority to NZ204327A priority patent/NZ204327A/en
Priority to ZA833686A priority patent/ZA833686B/xx
Priority to IN683/CAL/83A priority patent/IN157982B/en
Publication of JPS58201994A publication Critical patent/JPS58201994A/ja
Priority to ES528897A priority patent/ES8504463A1/es
Priority to FI840219A priority patent/FI86077C/fi
Priority to NO840215A priority patent/NO165510C/no
Priority to DK025084A priority patent/DK164510C/da
Priority to PH32453A priority patent/PH21344A/en
Priority to US07/113,212 priority patent/US5286647A/en
Publication of JPH0159878B2 publication Critical patent/JPH0159878B2/ja
Priority to JP5168345A priority patent/JPH07119240B2/ja
Priority to JP5168343A priority patent/JPH07121221B2/ja
Priority to US08/443,810 priority patent/US6051229A/en
Priority to US08/482,197 priority patent/US6051693A/en
Priority to US08/480,014 priority patent/US6051387A/en
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP57084843A 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法 Granted JPS58201994A (ja)

Priority Applications (31)

Application Number Priority Date Filing Date Title
JP57084843A JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法
CA000428517A CA1247538A (en) 1982-05-21 1983-05-19 Human-human hybridomas for solid tumors
CS833566A CZ280677B6 (cs) 1982-05-21 1983-05-19 Lidské monoklonální protilátky a způsob jejich výroby
SK3566-83A SK279249B6 (sk) 1982-05-21 1983-05-19 Ľudské monoklonálne protilátky a spôsob ich výroby
DE3382764T DE3382764T2 (de) 1982-05-21 1983-05-20 Humane-humane hybridomas für neoplasmen.
AT83902157T ATE114189T1 (de) 1982-05-21 1983-05-20 Humane-humane hybridomas für neoplasmen.
EP83902157A EP0109441B1 (en) 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms
JP58502264A JPS60501359A (ja) 1982-05-21 1983-05-20 新生物用ヒト↓−ヒトハイブリド−マ
ES522585A ES522585A0 (es) 1982-05-21 1983-05-20 Un metodo para determinar la presencia de una neoplasia.
HU832697A HU190908B (en) 1982-05-21 1983-05-20 Process for preparing humane-humane hybridomes and - by means thereof - monoclonal antibodies
PH28943A PH23031A (en) 1982-05-21 1983-05-20 Human-human hybridomas for cervical carcinoma
AU17729/83A AU560595B2 (en) 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms
PCT/US1983/000781 WO1983004313A1 (en) 1982-05-21 1983-05-20 Human-human hybridomas for neoplasms
IT21217/83A IT1203702B (it) 1982-05-21 1983-05-20 Ibridomi uomo-uomo per carcinomi cervicali
KR1019830002232A KR880001567B1 (ko) 1982-05-21 1983-05-21 경부암을 위한 인체-인체융합세포
IL68752A IL68752A (en) 1982-05-21 1983-05-22 Human hybridomas cell lines producing monoclonal antibodies capable of distinguishing neoplastic cells from normal cells,antibodies produced by them and method for determining the presence of a neoplasm by using said antibodies
ZA833686A ZA833686B (en) 1982-05-21 1983-05-23 Human human hybridomas for cervical carcinoma
IT8348350A IT8348350A0 (it) 1982-05-21 1983-05-23 Ibridoma uomo-uomo per carcinoma cervicale
NZ204327A NZ204327A (en) 1982-05-21 1983-05-23 Human monoclonal antibodies against human neoplastic cells;human hybridomas producing such antibodies;diagnostic procedures
IN683/CAL/83A IN157982B (show.php) 1982-05-21 1983-05-31
ES528897A ES8504463A1 (es) 1982-05-21 1984-01-16 Un metodo para la preparacion de anticuerpos monoclonales humanos especificos para las celulas neoplasicas
FI840219A FI86077C (fi) 1982-05-21 1984-01-19 Monoklonala antikroppar och metod att producera dessa.
NO840215A NO165510C (no) 1982-05-21 1984-01-20 Monoklonale antistoffer, samt anvendelse av dem in vitro for bestemmelse av naervaer av neoplasmer.
DK025084A DK164510C (da) 1982-05-21 1984-01-20 Humant hybridom, humant monoklonalt antistof opnaaet derfra, anvendelse af et saadant antistof og fremgangsmaade til fremstilling af et saadant antistof
PH32453A PH21344A (en) 1982-05-21 1985-06-25 Human-human hybridomas for cervical carcinoma
US07/113,212 US5286647A (en) 1982-05-21 1987-10-23 Human-human hybridomas for neoplasms
JP5168345A JPH07119240B2 (ja) 1982-05-21 1993-06-16 抗原特異的ヒト免疫グロブリン
JP5168343A JPH07121221B2 (ja) 1982-05-21 1993-06-16 抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ
US08/443,810 US6051229A (en) 1982-05-21 1995-05-18 Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions
US08/482,197 US6051693A (en) 1982-05-21 1995-06-07 CLNH11-specific antibodies
US08/480,014 US6051387A (en) 1982-05-21 1995-06-07 Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57084843A JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP5168343A Division JPH07121221B2 (ja) 1982-05-21 1993-06-16 抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ
JP5168345A Division JPH07119240B2 (ja) 1982-05-21 1993-06-16 抗原特異的ヒト免疫グロブリン

Publications (2)

Publication Number Publication Date
JPS58201994A true JPS58201994A (ja) 1983-11-25
JPH0159878B2 JPH0159878B2 (show.php) 1989-12-20

Family

ID=13842073

Family Applications (2)

Application Number Title Priority Date Filing Date
JP57084843A Granted JPS58201994A (ja) 1982-05-21 1982-05-21 抗原特異的ヒト免疫グロブリンの生産方法
JP58502264A Pending JPS60501359A (ja) 1982-05-21 1983-05-20 新生物用ヒト↓−ヒトハイブリド−マ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP58502264A Pending JPS60501359A (ja) 1982-05-21 1983-05-20 新生物用ヒト↓−ヒトハイブリド−マ

Country Status (13)

Country Link
EP (1) EP0109441B1 (show.php)
JP (2) JPS58201994A (show.php)
AT (1) ATE114189T1 (show.php)
AU (1) AU560595B2 (show.php)
CZ (1) CZ280677B6 (show.php)
DE (1) DE3382764T2 (show.php)
DK (1) DK164510C (show.php)
FI (1) FI86077C (show.php)
HU (1) HU190908B (show.php)
IN (1) IN157982B (show.php)
SK (1) SK279249B6 (show.php)
WO (1) WO1983004313A1 (show.php)
ZA (1) ZA833686B (show.php)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6012973A (ja) * 1983-03-11 1985-01-23 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ 悪性黒色腫のある患者のリンパ球からのヒトの単一クロ−ン抗体
JPS6024184A (ja) * 1983-03-09 1985-02-06 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ ガン細胞に対するヒトのモノクロ−ン抗体の反応
JPS60260597A (ja) * 1984-01-31 1985-12-23 アクゾ　ナムローゼ　フェンノートシャップ 自己由来のワクチン
JPS6133125A (ja) * 1984-07-25 1986-02-17 Morinaga & Co Ltd ヒト単クロ−ン性抗肺ガン細胞抗体
JPS61130300A (ja) * 1984-11-27 1986-06-18 ザ　ボ−ド　オブ　トラステイ−ズ　オブ　ザ　レランド　スタンフオ−ド　ジユニア　ユニバ−シテイ ヒトモノクロ−ナル抗体
JPS61204134A (ja) * 1984-10-15 1986-09-10 ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ−・オブ・カリフオルニア 癌細胞に対する抗体を産生するヒト−ヒトハイブリド−マ細胞系
JPS6299332A (ja) * 1985-10-26 1987-05-08 Hagiwara Yoshihide 悪性腫瘍用ヒトモノクロナル抗体複合剤
JPS62163686A (ja) * 1986-01-13 1987-07-20 Mitsubishi Chem Ind Ltd 抗体産生細胞株の樹立方法
WO1992020799A1 (fr) * 1991-05-22 1992-11-26 Hagiwara, Yoshihide Sequence d'acides amines d'anticorps monoclonal humain anticancer et sequence de bases d'adn codant pour ces acides amines

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4618577A (en) * 1983-02-09 1986-10-21 The Regents Of The University Of California Human-human hybridoma, CLNH5
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
CA1215331A (en) * 1983-03-04 1986-12-16 Tsann M. Chu Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
SE8401945L (sv) * 1983-04-08 1984-11-13 Kureha Chemical Ind Co Ltd Antikropp mot cancer i urinblasan hos menniska
WO1985002411A1 (en) * 1983-11-25 1985-06-06 The University Of Melbourne Cell line and monoclonal antibody
US4886745A (en) * 1984-03-30 1989-12-12 Syntex Inc. Monoclonal antibody specific for human basal cell surface antigen
EP0157613A3 (en) * 1984-03-30 1987-09-30 Syntex (U.S.A.) Inc. Monoclonal antibodies specific for human basal cell and malignant squamous cell protein, hybridomas therefor, malignancy test methods and diagnostic kits
US5106746A (en) * 1985-05-22 1992-04-21 E. I. Du Pont De Nemours And Company Process for the in vitro immunization of human splenocytes against tumor associated antigens
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
EP0222360A3 (en) * 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
AU7165891A (en) * 1989-12-18 1991-07-18 Board Of Regents, The University Of Texas System Tumor-specific, cell surface-binding monoclonal antibodies
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
DE69222909T2 (de) * 1991-08-16 1998-03-12 Toshiba Kawasaki Kk Monoklonaler Antikörper gegen ein Synaptophysin
PT1004315E (pt) 1997-08-15 2008-07-09 Chugai Pharmaceutical Co Ltd Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico
AU784460B2 (en) 1999-08-23 2006-04-06 Chugai Seiyaku Kabushiki Kaisha HM1.24 antigen expression potentiators
HUP0203486A2 (hu) 1999-10-01 2003-02-28 Chugai Seiyaku Kabushiki Kaisha Véralvadással összefüggő betegségek megelőzése és kezelése
EP1364657B1 (en) 2001-02-07 2016-12-28 Chugai Seiyaku Kabushiki Kaisha Remedies for myelocytic leukemia
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
AU2003257536A1 (en) 2002-08-27 2004-03-19 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein solution preparation
EP2261230B1 (en) 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Protein purification method
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US7863042B2 (en) 2003-06-18 2011-01-04 Chugai Seiyaku Kabushiki Kaisha Fucose transporter
JP4643450B2 (ja) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
EP2270152A1 (en) 2003-12-03 2011-01-05 Chugai Seiyaku Kabushiki Kaisha Expression system using mammalian beta-actin promoter
WO2005056605A1 (ja) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha ３量体以上の受容体を認識する改変抗体
PL1674111T3 (pl) 2004-07-09 2011-04-29 Chugai Pharmaceutical Co Ltd Przeciwciała anty-glipikan 3
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
EP1964574B1 (en) 2005-11-14 2016-09-07 Cellmid Limited Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AR057941A1 (es) 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
AR059213A1 (es) 2006-01-27 2008-03-19 Univ Keio Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal
IN2014DN10515A (show.php) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
JP5242382B2 (ja) 2006-04-14 2013-07-24 株式会社医学生物学研究所 エフェクター機能を有するポリペプチド変異体
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
JPWO2007145227A1 (ja) 2006-06-14 2009-11-05 中外製薬株式会社 造血幹細胞増加促進剤
MX2009000487A (es) 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
WO2008010556A1 (fr) 2006-07-21 2008-01-24 Chugai Seiyaku Kabushiki Kaisha Médicament agissant contre une maladie rénale
DE602006013809D1 (de) 2006-07-24 2010-06-02 Facultad De Medicina Universid Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
EP2548576B1 (en) 2006-08-14 2016-11-30 Chugai Seiyaku Kabushiki Kaisha Diagnosis of cancer using anti-desmoglein-3 antibodies
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
CA2665528C (en) 2006-10-12 2018-01-23 The University Of Tokyo Diagnosis and treatment of cancer using anti-ereg antibody
US20100061933A1 (en) 2006-10-20 2010-03-11 Naoki Kimura Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US20100111851A1 (en) 2007-01-05 2010-05-06 The University Of Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
CA2679266A1 (en) 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
WO2009001840A1 (ja) 2007-06-25 2008-12-31 Forerunner Pharma Research Co., Ltd. ADCC活性又はCDC活性を有する抗Prominin-1抗体
WO2009014263A1 (ja) 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
JP5264752B2 (ja) 2007-10-02 2013-08-14 中外製薬株式会社 インターロイキン６受容体阻害剤を有効成分とする移植片対宿主病治療剤
JP5620106B2 (ja) 2007-10-24 2014-11-05 株式会社糖鎖工学研究所 増強されたエフェクター機能を有するポリペプチド
WO2009063970A1 (ja) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. 抗gpr49抗体を用いる癌の診断および治療
TW200936160A (en) 2007-11-15 2009-09-01 Chugai Pharmaceutical Co Ltd Monoclonal antibodies that bind to anexelekto and uses thereof
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
RU2010133547A (ru) 2008-01-11 2012-02-20 Дзе Юниверсити Оф Токио (Jp) Анти-cldn антитела
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
EP2116261A1 (en) 2008-05-07 2009-11-11 Institut Pasteur Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
US8575314B2 (en) 2008-06-20 2013-11-05 National University Corporation Okayama University Antibody against oxidized LDL/β2GPI complex and use of the same
KR20110099762A (ko) 2008-12-26 2011-09-08 고쿠리츠다이가쿠호우진 도쿄다이가쿠 항ｌｇｒ７항체를 사용하는 암의 진단 및 치료
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
JP5723270B2 (ja) 2009-05-01 2015-05-27 国立大学法人 東京大学 抗カドヘリン抗体
JP5808052B2 (ja) 2009-05-29 2015-11-10 中外製薬株式会社 Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
TWI523661B (zh) 2009-07-31 2016-03-01 前田慎 Anti-IL-6 receptor antibody in the manufacture of inhibitors of metastatic inhibition of lung cancer metastasis to the liver
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
TWI505838B (zh) 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
RS57008B1 (sr) 2010-02-10 2018-05-31 Fujifilm Ri Pharma Co Ltd Anti-kadherin antitelo obeleženo radioaktivnim metalom
US20120321557A1 (en) 2010-02-26 2012-12-20 Forerunner Pharma Research Co., Ltd. Anti-icam3 antibody and use thereof
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
AU2011323784A1 (en) 2010-10-25 2013-05-30 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
JP6006640B2 (ja) 2010-10-29 2016-10-12 株式会社ペルセウスプロテオミクス 高い内在化能力を有する抗ｃｄｈ３抗体
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
EP2787078B1 (en) 2011-10-31 2019-05-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
CA2869704A1 (en) 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
EP2876160B1 (en) 2012-07-06 2020-05-13 Kyoto Prefectural Public University Corporation Differentiation marker for and differentiation control for ocular cells
SG11201502455TA (en) 2012-09-27 2015-05-28 Chugai Pharmaceutical Co Ltd Fgfr3 fusion gene and pharmaceutical drug targeting same
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
EP4671270A3 (en) 2013-12-27 2026-03-18 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
ES2756175T3 (es) 2013-12-27 2020-04-27 Chugai Pharmaceutical Co Ltd Genes mutantes guardián de fgfr y fármacos que se dirigen a los mismos
EP3185004A4 (en) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3263132B1 (en) 2015-02-27 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
KR20190133005A (ko) 2017-03-24 2019-11-29 젠야쿠코교가부시키가이샤 항 IgM/B 세포 표면 항원 이중 특이성 항체
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
US20220098290A1 (en) 2019-02-28 2022-03-31 Juntendo Educational Foundation Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
MX2021012163A (es) 2019-04-17 2022-01-31 Univ Hiroshima Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion.
WO2020250940A1 (ja) 2019-06-11 2020-12-17 小野薬品工業株式会社 免疫抑制剤
US20230149555A1 (en) 2020-04-06 2023-05-18 PhotoQ3 Inc. Medicament for killing tumor cells
IL300182A (en) 2020-07-28 2023-03-01 Chugai Pharmaceutical Co Ltd Preparation of a pre-filled syringe with a needle, supplied with a needle guard and containing a new modified antibody
KR20230057351A (ko) 2020-08-27 2023-04-28 각코우호우진 쥰텐도 항절단형 변이 calr-cd3 이중특이성 항체 및 의약 조성물
EP4306127A4 (en) 2021-03-12 2025-04-09 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment or prevention of myasthenia gravis
EP4412583A1 (en) 2021-10-04 2024-08-14 Novartis AG Surfactant stabilizers
JP7367262B1 (ja) 2021-12-01 2023-10-23 中外製薬株式会社 抗体含有製剤の調製方法
EP4483899A1 (en) 2022-02-25 2025-01-01 Juntendo Educational Foundation Medicine comprising combination of anti-mutant-calr antibody and another drug
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57502090A (show.php) * 1980-07-18 1982-11-25
NZ198851A (en) * 1980-11-07 1984-07-31 Wistar Inst Stable,continuous human myeloma cell line capable of hybridisation with antibody-producing cells:production of hybrid cell line

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024184A (ja) * 1983-03-09 1985-02-06 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ ガン細胞に対するヒトのモノクロ−ン抗体の反応
JPS6012973A (ja) * 1983-03-11 1985-01-23 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ 悪性黒色腫のある患者のリンパ球からのヒトの単一クロ−ン抗体
JPS60260597A (ja) * 1984-01-31 1985-12-23 アクゾ　ナムローゼ　フェンノートシャップ 自己由来のワクチン
JPS6133125A (ja) * 1984-07-25 1986-02-17 Morinaga & Co Ltd ヒト単クロ−ン性抗肺ガン細胞抗体
JPS61204134A (ja) * 1984-10-15 1986-09-10 ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ−・オブ・カリフオルニア 癌細胞に対する抗体を産生するヒト−ヒトハイブリド−マ細胞系
JPS61130300A (ja) * 1984-11-27 1986-06-18 ザ　ボ−ド　オブ　トラステイ−ズ　オブ　ザ　レランド　スタンフオ−ド　ジユニア　ユニバ−シテイ ヒトモノクロ−ナル抗体
JPS6299332A (ja) * 1985-10-26 1987-05-08 Hagiwara Yoshihide 悪性腫瘍用ヒトモノクロナル抗体複合剤
JPS62163686A (ja) * 1986-01-13 1987-07-20 Mitsubishi Chem Ind Ltd 抗体産生細胞株の樹立方法
WO1992020799A1 (fr) * 1991-05-22 1992-11-26 Hagiwara, Yoshihide Sequence d'acides amines d'anticorps monoclonal humain anticancer et sequence de bases d'adn codant pour ces acides amines

Also Published As

Publication number Publication date
DE3382764D1 (de) 1994-12-22
ZA833686B (en) 1984-09-26
DK164510C (da) 1992-11-23
CZ356683A3 (en) 1995-11-15
FI86077C (fi) 1992-07-10
AU560595B2 (en) 1987-04-09
FI840219A0 (fi) 1984-01-19
DK25084A (da) 1984-01-20
EP0109441A4 (en) 1986-09-22
IN157982B (show.php) 1986-08-09
SK356683A3 (en) 1998-08-05
ATE114189T1 (de) 1994-12-15
HU190908B (en) 1986-12-28
AU1772983A (en) 1983-12-16
DK164510B (da) 1992-07-06
DK25084D0 (da) 1984-01-20
FI840219L (fi) 1984-01-19
DE3382764T2 (de) 1995-03-16
EP0109441A1 (en) 1984-05-30
EP0109441B1 (en) 1994-11-17
JPS60501359A (ja) 1985-08-22
FI86077B (fi) 1992-03-31
JPH0159878B2 (show.php) 1989-12-20
WO1983004313A1 (en) 1983-12-08
SK279249B6 (sk) 1998-08-05
CZ280677B6 (cs) 1996-04-17

Similar Documents

Publication Publication Date Title
JPS58201994A (ja) 抗原特異的ヒト免疫グロブリンの生産方法
JP2648419B2 (ja) モノクローナル抗体混合物
US4634664A (en) Process for the production of human mono-clonal antibodies
CA1187010A (en) Cell-driven viral transfer in eukaryotes
KR930012104B1 (ko) 암-관련 항원-특이적 인간 면역 글로불린 및 인간 면역 글로불린을 생산하는 능력을 갖는 인간/인간 하이브리도마
JPS59137497A (ja) 抗原特異的免疫グロブリン生産性ヒト／ヒトハイブリド−マ及びその生産する抗体
US4752582A (en) Monoclonal antibodies to human glycophorin A and cell lines for the production thereof
EP0093775A1 (en) Monoclonal antibodies against brugia malayi
KR880001567B1 (ko) 경부암을 위한 인체-인체융합세포
US5330896A (en) Monoclonal antibodies to an autocrine growth factor antigen that binds to activated lymphocytes and cancer cells
EP0363703A1 (en) Method of producing human-human hybridomas, the production of monoclonal and polyclonal antibodies therefrom, and therapeutic use thereof
US5279958A (en) Surface protein of basal epidermal cells, antibodies capable of recognizing said protein, and their use, and hybrid cellular stocks capable of secreting such antibodies
Gaffar et al. Strategies for the design and use of tumor‐reactive human monoclonal antibodies
CN112094810B (zh) 单b细胞筛选方法及其在小分子单克隆抗体制备中的应用
JPH06153932A (ja) 抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ
US5039793A (en) Cytoplasmic protein of suprabasal epidermal cells, antibodies capable of recognizing said protein, and hybrid cellular stocks capable of secreting such antibodies
JPH07119240B2 (ja) 抗原特異的ヒト免疫グロブリン
Tilz et al. Antigenic Determinants of Migratory Cells
JPS59135898A (ja) 抗原特異的ヒト免疫グロブリンの生産方法
JP2599258B2 (ja) ガン関連抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ
JPS6359898A (ja) ガン関連抗原特異的ヒト免疫グロブリン
JPH05268988A (ja) ガン関連抗原特異的ヒト免疫グロブリン
JPH05207876A (ja) ガン関連抗原特異的ヒト免疫グロブリン生産性ヒト／ヒトハイブリドーマ
Brown The Production of Monoclonal Antibodies by Cell Fusion
JPH01500722A (ja) 膵臓α‐アミラーゼに対する抗体の産生及び診断への使用